TABLE 2.
Antimicrobial activity of CAZ-AVI and comparators against all blaOXA-48-like Enterobacterales isolates collected globally in 2016–2020c
| %S | %R | MIC50 | MIC90 | MIC range | |
|---|---|---|---|---|---|
| N = 1690 | |||||
| Amikacin | 56.1 | 39.5 | 8 | >64 | 0.25–>64 |
| Aztreonam | 9.5 | 89.5 | >64 | >128 | 0.03–>128 |
| CAZ-AVI | 78.6 | 21.4 | 1 | >128 | 0.015–>128 |
| Cefepime | 6.9 | 87.9 | >32 | >32 | 0.12–>32 |
| Colistina | 81.9 | 18.1 | 0.5 | >8 | 0.06–>8 |
| Imipenem | 10.4 | 76.4 | 8 | >8 | 0.06–>8 |
| Meropenem | 17 | 71.5 | 16 | >16 | 0.015–>16 |
| Pip/Taz | 0.9 | 98.9 | >64 | >128 | 0.25–>128 |
| Tigecyclineb | 95.5 | 5.3 | 1 | 2 | 0.06–>8 |
a
EUCAST breakpoints have been used.
b
FDA-approved breakpoints have been used.
c
N, total number of isolates; S, susceptibility; R, resistance; CAZ-AVI, ceftazidime–avibactam; Pip/taz, piperacillin/tazobactam.